7754
AnnJi Pharmaceutical Co., Ltd. develops drugs in the therapeutic areas of neurology, dermatology, and inflammatory disorders. It develops therapeutics, such as AJ201 for the treatment of spinal and bulbar muscular atrophy disease; AJ302, a histone deacetylase 6 inhibitor for the prevention and treatment of chemotherapy-induced peripheral neuropathy; and AJ303, an anti-fibrotic and anti-inflammato… Read more
7754 (7754) - Total Assets
Latest total assets as of June 2025: NT$783.74 Million TWD
Based on the latest financial reports, 7754 (7754) holds total assets worth NT$783.74 Million TWD as of June 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
7754 - Total Assets Trend (2021–2024)
This chart illustrates how 7754’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
7754 - Asset Composition Analysis
Current Asset Composition (December 2024)
7754's total assets of NT$783.74 Million consist of 74.2% current assets and 25.8% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 62.8% |
| Accounts Receivable | NT$816.00K | 0.1% |
| Inventory | NT$27.42 Million | 2.7% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$100.60 Million | 10.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2021–2024)
This chart illustrates how 7754's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: 7754's current assets represent 74.2% of total assets in 2024, an increase from 61.8% in 2021.
- Cash Position: Cash and equivalents constituted 62.8% of total assets in 2024, up from 58.7% in 2021.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 10.0% of total assets, a decrease from 30.0% in 2021.
- Asset Diversification: The largest asset category is intangible assets at 10.0% of total assets.
7754 Competitors by Total Assets
Key competitors of 7754 based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Halozyme Therapeutics Inc
NASDAQ:HALO
|
USA | $2.22 Billion |
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $7.59 Billion |
|
ESSA Pharma Inc
NASDAQ:EPIX
|
USA | $110.50 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
7754 - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - 7754 generates 0.10x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - 7754 is currently not profitable relative to its asset base.
7754 - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.99 | 3.20 | 5.03 |
| Quick Ratio | 4.74 | 3.08 | 5.03 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$434.18 Million | NT$ 582.25 Million | NT$ 834.23 Million |
7754 - Advanced Valuation Insights
This section examines the relationship between 7754's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 10.39 |
| Latest Market Cap to Assets Ratio | 0.11 |
| Asset Growth Rate (YoY) | -17.1% |
| Total Assets | NT$1.00 Billion |
| Market Capitalization | $111.88 Million USD |
Valuation Analysis
Below Book Valuation: The market values 7754's assets below their book value (0.11 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: 7754's assets decreased by 17.1% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for 7754 (2021–2024)
The table below shows the annual total assets of 7754 from 2021 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.00 Billion | -17.05% |
| 2023-12-31 | NT$1.21 Billion | +123.19% |
| 2022-12-31 | NT$541.23 Million | -18.80% |
| 2021-12-31 | NT$666.54 Million | -- |